GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (HKSE:06826) » Definitions » Piotroski F-Score

Shanghai Haohai Biological Technology Co (HKSE:06826) Piotroski F-Score : N/A (As of Apr. 20, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Haohai Biological Technology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's Piotroski F-Score or its related term are showing as below:

During the past 11 years, the highest Piotroski F-Score of Shanghai Haohai Biological Technology Co was 7. The lowest was 1. And the median was 2.


Shanghai Haohai Biological Technology Co Piotroski F-Score Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haohai Biological Technology Co Piotroski F-Score Chart

Shanghai Haohai Biological Technology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 - 5.00 6.00 -

Shanghai Haohai Biological Technology Co Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 N/A 6.00 N/A -

Competitive Comparison of Shanghai Haohai Biological Technology Co's Piotroski F-Score

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Haohai Biological Technology Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 97.694 + 105.96 + 148.285 + 116.276 = HK$468 Mil.
Cash Flow from Operations was 0 + 82.526 + 271.853 + 112.466 = HK$467 Mil.
Revenue was 714.37 + 701.745 + 816.502 + 738.105 = HK$2,971 Mil.
Gross Profit was 474.278 + 485.71 + 584.788 + 518.252 = HK$2,063 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(7604.87 + 7771.843 + 7813.715 + 7796.529 + 7977.217) / 5 = HK$7792.8348 Mil.
Total Assets at the begining of this year (Sep23) was HK$7,605 Mil.
Long-Term Debt & Capital Lease Obligation was HK$184 Mil.
Total Current Assets was HK$4,078 Mil.
Total Current Liabilities was HK$949 Mil.
Net Income was 20.905 + 92.461 + 135.691 + 130.407 = HK$379 Mil.

Revenue was 581.673 + 696.214 + 767.451 + 717.519 = HK$2,763 Mil.
Gross Profit was 377.691 + 497.746 + 542.153 + 522.645 = HK$1,940 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(0 + 7696.843 + 0 + 7934.468 + 7604.87) / 5 = HK$7745.39366667 Mil.
Total Assets at the begining of last year (Sep22) was HK$0 Mil.
Long-Term Debt & Capital Lease Obligation was HK$284 Mil.
Total Current Assets was HK$3,986 Mil.
Total Current Liabilities was HK$622 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Haohai Biological Technology Co's current Net Income (TTM) was 468. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai Haohai Biological Technology Co's current Cash Flow from Operations (TTM) was 467. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=468.215/7604.87
=0.06156778

ROA (Last Year)=Net Income/Total Assets (Sep22)
=379.464/0
=

Shanghai Haohai Biological Technology Co's return on assets of this year was 0.06156778. Shanghai Haohai Biological Technology Co's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai Haohai Biological Technology Co's current Net Income (TTM) was 468. Shanghai Haohai Biological Technology Co's current Cash Flow from Operations (TTM) was 467. ==> 467 <= 468 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=183.628/7792.8348
=0.0235637

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=284.277/7745.39366667
=0.03670272

Shanghai Haohai Biological Technology Co's gearing of this year was 0.0235637. Shanghai Haohai Biological Technology Co's gearing of last year was 0.03670272. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=4077.683/948.525
=4.29897262

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=3985.956/622.229
=6.40593094

Shanghai Haohai Biological Technology Co's current ratio of this year was 4.29897262. Shanghai Haohai Biological Technology Co's current ratio of last year was 6.40593094. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai Haohai Biological Technology Co's number of shares in issue this year was 233.486. Shanghai Haohai Biological Technology Co's number of shares in issue last year was 241.334. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2063.028/2970.722
=0.6944534

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1940.235/2762.857
=0.70225676

Shanghai Haohai Biological Technology Co's gross margin of this year was 0.6944534. Shanghai Haohai Biological Technology Co's gross margin of last year was 0.70225676. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=2970.722/7604.87
=0.39063416

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=2762.857/0
=

Shanghai Haohai Biological Technology Co's asset turnover of this year was 0.39063416. Shanghai Haohai Biological Technology Co's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+0+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai Haohai Biological Technology Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Shanghai Haohai Biological Technology Co  (HKSE:06826) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai Haohai Biological Technology Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haohai Biological Technology Co Business Description

Traded in Other Exchanges
Address
No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to single operating segment which is the manufacture and sale of biologicals, medical hyaluronate and intraocular lens, research and development of biological engineering and pharmaceutical products and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Dalton Investments Llc 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Templeton Investment Counsel, Llc 2102 Investment manager
Kabouter Management Llc 2102 Investment manager
Royal Bank Of Canada 2201 Interest of corporation controlled by you
Kabouter International Insight Fund, Llc 2102 Investment manager
Prudence Investment Management (hong Kong) Limited 2102 Investment manager

Shanghai Haohai Biological Technology Co Headlines

No Headlines